![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaborat... Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections. Show more
-ย ย 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks -ย ย Efficacy: 76% of 6E10...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.67 | -17.0931422723 | 9.77 | 9.9471 | 7.44 | 402822 | 7.96386921 | CS |
4 | 1.12 | 16.0458452722 | 6.98 | 10.14 | 6.58 | 490617 | 8.24428932 | CS |
12 | -2 | -19.801980198 | 10.1 | 10.84 | 6.38 | 363321 | 8.22847768 | CS |
26 | -0.947 | -10.4675583066 | 9.047 | 29.8 | 6.38 | 1203643 | 17.47220517 | CS |
52 | -8.9 | -52.3529411765 | 17 | 29.8 | 6.38 | 762195 | 16.17748319 | CS |
156 | -15.2 | -65.2360515021 | 23.3 | 29.8 | 5.31 | 928919 | 16.08863559 | CS |
260 | -126.6 | -93.986636971 | 134.7 | 269.8 | 5.31 | 1161635 | 58.71591206 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions